Breast Cancer is the leading type of cancer in women. According to WHO, one in every 8 women in US is at the risk of developing a breast abnormality in her life time. It is well-established that early diagnosis is very critical in saving a life of a cancer patient. We at NIRAMAI have developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. Our solution can detect cancer at a much earlier stage than traditional diagnostic methods and self-examination and can therefore improve survival rates. Our method of breast cancer screening can detect tumors 5 times smaller than what clinical exam can detect, is non-contact, painless and free of any radiation, apart from being low-cost, and universally accessible. With our solution, women of all age groups can undergo frequent screening without any side-effects.
The current gold standard for breast cancer screening, Mammography, requires high capital cost for equipment and experienced radiographers. It is recommended once every 2 years and only to women above 45 years because it cannot identify tumours effectively for younger women, and uses of X-rays for scanning, which can make women more susceptible to cancer if screened multiple times. In addition, it is also very painful for the subject (about 20 pounds weight is applied on the breasts while screening). Other common method of clinical exam can detect tumors only after they are large enough to be palpable.
NIRAMAI solution uses a high resolution thermal sensing device and cloud hosted analytics solution for analysing the thermal images. Our SaaS solution uses big data analytics, artificial intelligence and machine learning for reliable, early and accurate breast cancer screening. The innovative methods used in our solution have led to multiple US patents. Our novel algorithms have also been peer-reviewed in international scientific conferences.
Our cancer screening tool, SMILE, has been tested on 300 patients data from 2 hospitals and one diagnostic center. Early results from these tests indicate very high accuracy that is comparable and sometime better that Mammography. We have started 2 clinical trials with established hospitals to perform large scale, statistically significant clinical trials. We are working with multiple partners to make our solution commercially available by mid 2017.
If you wish to sign up for a screening test with our solution, please share your contact details here.
We provide complete hardware-software solution for breast cancer screening in three modes. (a) Sturdy, compact screening device with cloud processing for specialty hospitals (b) Low-cost, handheld device with real-time cloud-based diagnostics for independent medical practitioners (c) A portable solution for large-scale screenings.
If you are interested in partnering with us to deploy the solution in your diagnostic centre, please drop us a note using the contact form.
More accurate than physical examination
Detects cancer long before a lump can be felt
No harmful radiation
No-touch, non-invasive, not painful
Works for women of all ages, even below 40 years
Portable, light, small screening device
Automated detection using Machine Intelligence
Radiation-free. Does not require any incision.
No one touches or even sees you
Best in class sensitivity & specificity.
Chief Executive Officer
Chief Operating Officer
Senior Research Engineer
Senior Solution Architect
Customer Success Manager